Nagendran Sukumar's Form 4 filing
Taysha Gene Therapies, Inc. (TSHA) · filed May 18, 2023
- Accession no.
- 0001209191-23-030661
- Filed
- May 18, 2023
- Trade date
- May 16, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market purchases total $3.40K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Nagendran SukumarCIK 0001665124 | Director, Officer (President and Head of R&D) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 16, 2023 | Common Stock | PPurchaseAcquired | +5,000 | $0.68 | +$3,400 | 34,226 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.